Find your next paid study

SWOG Cancer Research NetworkNCT06769126

~$75 – $3,000

Actual pay is set by the research site.

Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8

Phase II Study of CIMAVAX-EGF in Combination With KRAS G12C Inhibitors as Treatment for Advanced Stage KRAS G12C Mutated NSCLC

This phase II trial tests how well giving CIMAvax-EGF with KRAS G12C inhibitor (sotorasib or adagrasib) for the treatment of patients with KRAS G12C mutated no…

Roswell Park Cancer InstituteNCT07543172

~$75 – $3,000

Actual pay is set by the research site.

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung canc…

University of Michigan Rogel Cancer CenterNCT06225427

~$150 – $3,000

Actual pay is set by the research site.

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+2 more

A Phase 2 Trial of SX-682 and Atezolizumab in Patients With Advanced NSCLC Who Progressed on Prior Chemotherapy and Immune Checkpoint Inhibitor (ICI) Therapy

This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it fir…

University of WashingtonNCT07322341

~$75 – $2,000

Actual pay is set by the research site.

Clinical Stage 0 Cutaneous Melanoma AJCC v8Clinical Stage I Cutaneous Melanoma AJCC v8Clinical Stage IA Cutaneous Melanoma AJCC v8+41 more

Role of Microbiome in the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients…

Lung Non-Small Cell CarcinomaMediastinal NeoplasmPleural Neoplasm+4 more

Phase II Trial of Lung Chemoemobolization

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. T…

City of Hope Medical CenterNCT05672108

~$75 – $2,000

Actual pay is set by the research site.

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more

A Phase Ib Trial of PBF-1129 and Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

This phase I trial studies the side effects and best dose of PBF-1129 in combination with nivolumab in treating patients with non-small cell lung cancer that h…

~$150 – $4,500

Actual pay is set by the research site.

Dwight OwenNCT05234307

Vulvar AdenocarcinomaPDAC - Pancreatic Ductal AdenocarcinomaGastric Adenocarcinoma+6 more

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients …

~$150 – $4,200

Actual pay is set by the research site.

Avacta Life Sciences Ltd

Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+2 more

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant …

Emory UniversityNCT04762199

~$150 – $3,000

Actual pay is set by the research site.

Non Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNon-small Cell Carcinoma+2 more

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therap…

Memorial Sloan Kettering Cancer CenterNCT05657873

~$75 – $2,000

Actual pay is set by the research site.

Observational

An Interventional Study of PET/CT Changes During Chemoimmunotherapy and Radiation Therapy for Patients With Metastatic NSCLC (PET Bright)

This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therap…

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

University of WashingtonNCT04151940

~$10 – $750

Actual pay is set by the research site.

Phase 3

A Phase 3 Open-Label, Randomized Controlled Trial of BL-M14D1 and Atezolizumab vs. Standard-of-Care Therapy in Patients With First-Line Extensive-Stage Small Cell Lung Cancer

The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult pa…

Small Cell Lung Cancer Extensive StageSmall-cell Lung CancerSmall Cell Carcinoma+5 more